On October 15, 2019 Nurix Therapeutics, Inc., a company developing therapies that control disease-causing proteins, reported that Arthur Sands, M.D., Ph.D., chief executive officer, and Gwenn Hansen, Ph.D., senior vice president, research, will present at the Targeted Protein Degradation Summit 2019 being held on October 22-24, 2019 at the Hilton Boston Logan Airport in Boston (Press release, Nurix Therapeutics, OCT 15, 2019, View Source [SID1234542262]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation Details:
Section: Workshop E
Title: Enabling Technologies for Targeted Degradation: Ligand Discovery using DNA-Encoded Small Molecule Libraries
Presenter: Gwenn Hansen, Ph.D.
Date: Tuesday, October 22, 2019
Time: 2:30 p.m. EDT

Section: Unlocking the Full Therapeutic & Investment Potentials of TPD Through Successful Clinical Development
Title: Developing Ligase Inhibitor and Activators for Cancer Therapy
Presenter: Arthur Sands, M.D., Ph.D.
Date: Wednesday, October 23, 2019
Time: 4:10 p.m. EDT